SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Kanes Stephen (Last) (First) (Middle) C/O SAGE THERAPEUTICS, INC. 215 FIRST STREET (Street) CAMBRIDGE MA 02142 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Sage Therapeutics, Inc. [ SAGE ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Medical Officer
	3. Date of Earliest Transaction (Month/Day/Year) 12/08/2016
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$38.25	12/08/2016		A		14,400		12/08/2016	01/23/2025	Common Stock	14,400	$0.00	68,000(1)	D

Explanation of Responses:

1. The securities awarded on 1/23/2015 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 5,000 shares of common stock vested on the one year anniversary of the Vesting Start Date with 15,000 shares vesting in 36 equal monthly installments thereafter. Options to purchase 48,000 shares of common stock vest periodically over four years from the grant date upon the company reaching certain milestone requirements, of which the performance criteria were met with the respect of 14,400 shares.

Remarks:

	/s/ Anne Marie Cook as Attorney-in-Fact for Stephen Kanes	12/14/2016
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

           POWER OF ATTORNEY


I, the undersigned, hereby authorize and designate
Anne Marie Cook (SVP, General Counsel), Kimi Iguchi
(Chief Financial Officer),Erin Lanciani (Vice President,
Human Resources), for as long as they remain employees
of Sage Therapeutics, Inc., and
Laurie Burlingame of Goodwin Procter, each acting singly,
or their successors in role or any of them acting as them
acting as agent and attorney-in-fact, with full power of
substitution, to:

          (1)  prepare and sign on my behalf any Form 4
          or Form 5 pursuant to Section 16 of the
          Securities Exchange Act of 1934, as amended,
          and file the same with the Securities
          Exchange Commission, NASDAQ, NYSE, and
          each stock exchange on which shares of
          Common Stock or other securities of Sage
          Therapeutics, Inc.are listed, as required by law;

          (2)  prepare and sign on my behalf any Form 144
          pursuant to the Securities Act of 1933, as
	  amended, and file the same with the Securities
          Exchange Commission, NYSE, and
          each stock exchange on which Sage
          Therapeutics, Inc.'s common stock or
          other securities are listed, as required by law;
          and

          (3) take any other action necessary or proper
          in connection with the foregoing.

Unless earlier revoked under the next sentence,
this Power of Attorney shall remain in effect as long as
I am an executive officer of Sage Therapeutics, Inc. and shall
not be affected by my subsequent disability or incompetence.
I make revoke this Power of Attorney by written notice
delivered, in person or by nationally recognized courier,
to the attention of SVP, General Counsel of Sage Therapeutics.

Date:    April 21, 2016

/s/ Steve Kanes

Steve Kanes
(name and signature of Officer or Director)